Amarantus BioScience Holdings Inc. (AMBSD) ended June with a blockbuster patent announcement: U.S. Patent No. 9,066,903 entitled, "Pharmacological Treatment of Parkinson's Disease." The patent covers methods for the administration of eltoprazine, in combination with the anti-Parkinson's drug, levodopa (L-DOPA), for the treatment of Parkinson's disease.
"We are very pleased with the issuance by the USPTO of the patent covering the use of eltoprazine in treating patients with Parkinson's disease receiving L-DOPA and who suffer from L-DOPA induced dyskinesia. This new issuance helps the Company continue to build our intellectual property estate for eltoprazine," said Gerald Commissiong, Amarantus President and CEO , one of the 50 Most Important African-Americans in Technology who previewed the news at Innovation&Equity 2015 in January.
Aphios Corporation announced that it was granted United States Patent No. 9,034,347 directed to the treatment of neurodegenerative diseases such as Huntington's disease, Parkinson's disease, Down syndrome and Alzheimer's disease.Neurodegenerative diseases, such as Alzheimer's disease (AD), Huntington's disease, Parkinson's disease, Kuru, Creutzfeldt-Jakob disease and other spongiform encephalopathies remain major health problems. Currently there are very limited means to treat these diseases. Alzheimer's, Huntington's and Parkinson's diseases tend to manifest themselves in older individuals and as the diseases progress; the afflicted individuals are less able tocare for themselves.
Another 50 Most selectee: Dr. Trevor Castor, CEO , Aphios Corporation states that, "It is therefore highly desirable to have simple therapies which can be administered (e.g. oral formulations) without the need for specially trained healthcare providers."Dr. Castor continues, "Our recent in vitrostudies have shown that our lead Alzheimer's disease drug candidate, APH-1104, a potent analog of Bryostatin-1, is neuroprotective by α-secretase activation via novel PKC isoforms, down-regulation of pro-inflammatory and angiogenic processes and the substitution of β-amyloid for its soluble and harmless relative, sAPP-α at concentrations which are orders of magnitude lower than conventional APPmodulators. Ourin vivo studies show that we can rapidly restore cognitive performance in AD-transgenic mice by oral administration of an oil-based formulation of Bryostatin-1."
A third 50 Most selectee, Mike Molaire of Molecular Glasses posted "
Molaicular™ HT 1700 High-Triplet Hole-Transporting NONcrsytallizable™ Organic Semiconductor
Molecular Glasses filed for patent protection for its new class of organic semiconductor materials for OLED and other organic electronic applications, said Mike Molaire, president.
The filing converts prior provisional applications into full U.S. and PCT patent filings, but also incorporates additional proprietary aspects of the Company’s material and process that were recently developed. The new patent filings cover the preparation of novel noncrystallizable hole-transporting, electron-transporting, ambipolar, and luminescent composition of matter, including procedures to ensure their purity. Organic light emitting diode (OLED) is poised to challenge light emitting diode (LED), and liquid crystal (LCD) in flat panel displays, flexible displays and lighting applications. OLED display has an advantage over LCD with its high response speed, wide viewing angle and high contrast in dark settings.